|Bid||268.80 x 1300|
|Ask||277.80 x 1000|
|Day's Range||272.00 - 277.20|
|52 Week Range||152.24 - 325.54|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||116.87|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Parexel and Veeva Systems (NYSE: VEEV) today announced a strategic collaboration to accelerate clinical trials through technology and process innovation. The unique collaboration combines the best of each company's experience across thousands of studies worldwide – Parexel as a leading clinical research organization (CRO) and Veeva as the technology innovator powering trials – to improve study efficiency and get new therapies to patients faster.
Global CRO takes action to further modernize study operations, adopting the Veeva Vault Clinical Operations Suite for greater efficiency and speed.
Boehringer Ingelheim is standardizing on Veeva CRM Engage Meeting to drive more valued interactions between its global field organization and HCPs.